AU2022236492B2 - Therapeutic binding molecule that binds to ccr9 - Google Patents

Therapeutic binding molecule that binds to ccr9 Download PDF

Info

Publication number
AU2022236492B2
AU2022236492B2 AU2022236492A AU2022236492A AU2022236492B2 AU 2022236492 B2 AU2022236492 B2 AU 2022236492B2 AU 2022236492 A AU2022236492 A AU 2022236492A AU 2022236492 A AU2022236492 A AU 2022236492A AU 2022236492 B2 AU2022236492 B2 AU 2022236492B2
Authority
AU
Australia
Prior art keywords
ser
seq
ccr9
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022236492A
Other languages
English (en)
Other versions
AU2022236492A1 (en
AU2022236492A9 (en
Inventor
Peter CARIUK
Catherine Eugenie Chaillan Huntington
Lorraine IRVING
Josquin Arnaud NYS
David Gareth REES
Aidan RILEY
Matthew Robinson
Darren Jonathan SCHOFIELD
Albert George Thom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2022236492A1 publication Critical patent/AU2022236492A1/en
Publication of AU2022236492A9 publication Critical patent/AU2022236492A9/en
Application granted granted Critical
Publication of AU2022236492B2 publication Critical patent/AU2022236492B2/en
Priority to AU2025205131A priority Critical patent/AU2025205131A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2022236492A 2021-03-18 2022-03-17 Therapeutic binding molecule that binds to ccr9 Active AU2022236492B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205131A AU2025205131A1 (en) 2021-03-18 2025-07-03 Therapeutic binding molecules

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162603P 2021-03-18 2021-03-18
US63/162,603 2021-03-18
PCT/EP2022/057029 WO2022195028A2 (en) 2021-03-18 2022-03-17 Therapeutic binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205131A Division AU2025205131A1 (en) 2021-03-18 2025-07-03 Therapeutic binding molecules

Publications (3)

Publication Number Publication Date
AU2022236492A1 AU2022236492A1 (en) 2023-10-26
AU2022236492A9 AU2022236492A9 (en) 2023-11-09
AU2022236492B2 true AU2022236492B2 (en) 2025-04-10

Family

ID=81327268

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022236492A Active AU2022236492B2 (en) 2021-03-18 2022-03-17 Therapeutic binding molecule that binds to ccr9
AU2025205131A Pending AU2025205131A1 (en) 2021-03-18 2025-07-03 Therapeutic binding molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205131A Pending AU2025205131A1 (en) 2021-03-18 2025-07-03 Therapeutic binding molecules

Country Status (19)

Country Link
US (3) US12049506B2 (https=)
EP (2) EP4308607A2 (https=)
JP (2) JP7574467B2 (https=)
KR (2) KR20250069981A (https=)
CN (1) CN116997571A (https=)
AR (1) AR125142A1 (https=)
AU (2) AU2022236492B2 (https=)
CA (1) CA3212630A1 (https=)
CL (1) CL2023002759A1 (https=)
CO (1) CO2023013566A2 (https=)
CR (1) CR20230488A (https=)
EC (1) ECSP23078844A (https=)
IL (2) IL305690B2 (https=)
MA (1) MA71643A (https=)
MX (1) MX2023010917A (https=)
NZ (1) NZ804536A (https=)
TW (1) TWI872319B (https=)
WO (1) WO2022195028A2 (https=)
ZA (1) ZA202309418B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
EP4417623A1 (en) * 2023-02-15 2024-08-21 Fundació Institut de Recerca Contra la Leucèmia Josep Carreras Ccr9 targeting moiety for the treatment of ccr9-positive cancer
EP4578874A1 (en) 2023-12-29 2025-07-02 SunRock Biopharma S.L. Anti-ccr9 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075269A1 (en) * 2013-11-25 2015-05-28 Consejo Superior De Investigaciones Científicas Antibodies against ccr9 and applications thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075269A1 (en) * 2013-11-25 2015-05-28 Consejo Superior De Investigaciones Científicas Antibodies against ccr9 and applications thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOMOVILLA-CRESPO BEATRIZ ET AL: "92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts", FRONTIERS IN IMMUNOLOGY, vol. 9, 29 January 2018 (2018-01-29), XP055928916, DOI: 10.3389/fimmu.2018.00077 *
Zabel, B.A. et al. J Exp Med 1 November 1999; 190 (9): 1241–1256. *

Also Published As

Publication number Publication date
AU2022236492A1 (en) 2023-10-26
JP7574467B2 (ja) 2024-10-28
CA3212630A1 (en) 2022-09-22
BR112023018331A2 (pt) 2023-12-12
KR102805310B1 (ko) 2025-05-13
AU2025205131A1 (en) 2025-07-24
AR125142A1 (es) 2023-06-14
US12049506B2 (en) 2024-07-30
MA71643A (fr) 2025-05-30
KR20230158526A (ko) 2023-11-20
IL318237A (en) 2025-03-01
IL305690B1 (en) 2025-06-01
EP4406592A3 (en) 2024-10-30
NZ804536A (en) 2024-12-20
TWI872319B (zh) 2025-02-11
WO2022195028A2 (en) 2022-09-22
ECSP23078844A (es) 2023-11-30
MX2023010917A (es) 2023-09-27
EP4308607A2 (en) 2024-01-24
US20250084174A1 (en) 2025-03-13
US20240174758A1 (en) 2024-05-30
TW202304985A (zh) 2023-02-01
KR20250069981A (ko) 2025-05-20
IL305690B2 (en) 2025-10-01
WO2022195028A3 (en) 2022-10-27
CO2023013566A2 (es) 2023-10-30
CN116997571A (zh) 2023-11-03
ZA202309418B (en) 2024-06-26
EP4406592A2 (en) 2024-07-31
JP2025011259A (ja) 2025-01-23
IL305690A (en) 2023-11-01
CL2023002759A1 (es) 2024-02-16
US20220306754A1 (en) 2022-09-29
AU2022236492A9 (en) 2023-11-09
JP2024516769A (ja) 2024-04-17
CR20230488A (es) 2023-12-12

Similar Documents

Publication Publication Date Title
KR102781536B1 (ko) 항-4-1bb 항체 및 이의 용도
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
RU2563344C2 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ
US20250084174A1 (en) Therapeutic binding molecules
KR20250016456A (ko) 인간 il-4ra에 대한 항체 및 이의 용도
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP2021536437A (ja) 抗ｐｄ−ｌ１／抗ｌａｇ３二重特異性抗体およびその使用
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
US20240383983A1 (en) Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
CN118369341A (zh) 抗hla-g抗体
US20240270839A1 (en) Novel anti-claudin18 antibodies
AU2015392603B2 (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
WO2018059465A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
HK40113316A (en) Therapeutic binding molecules
EA052530B1 (ru) Терапевтическая связывающая молекула, которая связывается с ccr9
BR122024010248A2 (pt) Molécula de ligação que se liga a ccr9, agente terapêutico, método para avaliar a depleção de células que expressam ccr9 por uma molécula de ligação, polinucleotídeo isolado, vetor, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, método para detectar a presença de um polipeptídeo ccr9 em uma amostra, usos e kits
BR112023018331B1 (pt) Molécula de ligação que se liga a ccr9
KR20250012013A (ko) 신규 tm4sf5-특이적 항체

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)